Literature DB >> 9250158

Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.

H Hayashi1, H Miyamoto, T Ito, Y Kameda, N Nakamura, Y Kubota, H Kitamura.   

Abstract

Our studies suggested that adenocarcinoma of the peripheral lung mostly develops by several steps from atypical adenomatous hyperplasia through early adenocarcinoma to overt adenocarcinoma, and that some p53 abnormalities play an important role in this progression. In the present study, we examined by immunohistochemistry the expression of p53-inducible cyclin-dependent kinase inhibitor p21Waf1/Cip1 (p21) in the cells at various developmental stages of lung adenocarcinoma (32 lesions of adenomatous hyperplasia, 14 of early adenocarcinoma, 23 of well differentiated adenocarcinoma, and 17 of moderately or poorly differentiated adenocarcinoma) in comparison with 19 reactive proliferative lesions and analyzed the relationship between p53 and p21 expression. Bronchioalveolar cells in the normal lung expressed very little or no p21 and no p53 expression. In not only reactive but also neoplastic lesions regardless of their developmental stage, the cells expressed p21 at various frequencies. The average labeling indices ranged from 5.4 to 13.8%, and there was no significant difference between any of these categories. The expression of p21, however, tended to be relatively low in moderately and poorly differentiated adenocarcinomas (5.5%) compared to well differentiated adenocarcinomas (12.2%), and high-level p21 expressors (10% < or = positive cells) were more frequent in the latter group (1 of 17 (6%) versus 3 of 23 (35%), P < 0.05), suggesting that p21 expression is affected by the degree of differentiation of the neoplastic cells. Although the correlation was positive between the expression of p21 and p53 in reactive lesions (r = 0.88; P < 0.001), none was found in neoplastic lesions at any step or grade (-0.12 < or = r < or = 0.26). These results indicated that p21 expression depends upon p53 expression in reactive lung cells, whereas p21 expression is at least in part independent of that of p53 from the earliest to the most fully developed step of lung adenocarcinoma tumorigenesis. We concluded that disruption of the p53-dependent cell cycle regulation is a very early event in the tumorigenesis of lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9250158      PMCID: PMC1857989     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Authors:  S M Bodner; J D Minna; S M Jensen; D D'Amico; D Carbone; T Mitsudomi; J Fedorko; D L Buchhagen; M M Nau; A F Gazdar
Journal:  Oncogene       Date:  1992-04       Impact factor: 9.867

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation.

Authors:  C Doglioni; P Pelosio; L Laurino; E Macri; E Meggiolaro; F Favretti; M Barbareschi
Journal:  J Pathol       Date:  1996-07       Impact factor: 7.996

4.  Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction.

Authors:  S J Meltzer; J Yin; Y Huang; T K McDaniel; C Newkirk; O Iseri; B Vogelstein; J H Resau
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

5.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

6.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

7.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

Review 8.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

9.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

View more
  5 in total

Review 1.  Pulmonary preinvasive neoplasia.

Authors:  K M Kerr
Journal:  J Clin Pathol       Date:  2001-04       Impact factor: 3.411

2.  Transition from squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung.

Authors:  H Kanazawa; M Ebina; N Ino-Oka; M Shimizukawa; T Takahashi; S Fujimura; T Imai; T Nukiwa
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

3.  The role of p53 in bleomycin-induced DNA damage in the lung. A comparative study with the small intestine.

Authors:  K Okudela; T Ito; H Mitsui; H Hayashi; N Udaka; M Kanisawa; H Kitamura
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

Review 4.  Preneoplastic lesions of the lung.

Authors:  Alissa K Greenberg; Herman Yee; William N Rom
Journal:  Respir Res       Date:  2002-04-04

5.  The association between atypical adenomatous hyperplasia and primary lung cancer.

Authors:  A D Chapman; K M Kerr
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.